2025-10-11 - Analysis Report
Okay, here's an analysis of Northrop Grumman (NOC) based on the data you provided.

**1. Performance Relative to S&P 500 (VOO)**

*   **Ticker:** NOC
*   **Company:** Northrop Grumman Corp
*   **Description:** Northrop Grumman is a global aerospace and defense technology company.

**Key Numbers:**

*   NOC Cumulative Return: 63.19%
*   VOO Cumulative Return: 99.08%
*   Difference: -34.1%
*   Relative Difference (Volatility Adjusted): 18.6 (Indicates NOC is positioned relatively low within its historical performance range compared to VOO)

**Alpha/Beta Analysis (Selected Periods):**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 46.0%  | 65.6%  | 17.0%  | 0.0  | 43.9   |
| 2016-2018  | -2.0%  | 74.3%  | -17.0% | 0.0  | 35.1   |
| 2020-2022  | 18.0%  | 79.9%  | 19.0%  | 0.3  | 78.1   |
| 2022-2024  | -15.0% | 82.7%  | -36.0% | 0.2  | 67.2   |
| 2023-2025  | 13.0%  | 82.1%  | -51.0% | 0.1  | 90.0   |

**Analysis:**

*   **Underperformance:** NOC has underperformed the S&P 500 significantly in terms of cumulative return.
*   **Volatility:** The provided Alpha/Beta analysis shows that during certain periods (e.g., 2022-2024), NOC experienced negative alpha, indicating underperformance relative to its risk-adjusted benchmark. Beta values are generally low, suggesting less correlation with the overall market.
*   **Capitalization:** Market capitalization has fluctuated, with a notable increase in the most recent period (2023-2025).

**2. Recent Stock Price Movement**

*   **Current Price:** $628.83
*   **Last-market:** price': 628.83, 'previousClose': 635.01, 'change': -0.97 (-0.97% change)
*   **5-day Moving Average:** $623.29
*   **20-day Moving Average:** $595.19
*   **60-day Moving Average:** $583.39

**Analysis:**

*   **Recent Dip:** The stock price has decreased slightly.
*   **Uptrend:** The price is above all moving averages, indicating an upward trend over the short, medium, and longer terms.  The 5-day moving average is above the 20-day, which is above the 60-day, further supporting this trend.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 82.93 (Overbought)
*   **PPO:** 0.70
*   **Hybrid Signal:** Buy 100% of cash. Monthly invest 0.8% of total investment.
*   **Recent (20-day) Relative Difference Change:** 6.2 (+) (Short-term Increase)
*   **Expected Return:** -13.3% (Long-term, relative to S&P 500)

**Analysis:**

*   **High Risk Tolerance Justified:** MRI suggests the investment is relatively safe.
*   **Overbought Condition:** RSI indicates the stock may be overbought and a potential correction is possible.
*   **Positive Momentum:** PPO being positive suggests upward price momentum.
*   **Contradictory Signals:** The "Buy" signal is tempered by the overbought RSI and the negative expected return.
*   **Recent negative change of the price should be considered**
*   **The recent Relative Difference Change (6.2) confirms this upward trend.**
*   **Important Consideration:** The negative expected return suggests that, despite recent positive momentum, long-term projections indicate potential underperformance compared to the S&P 500. This could be due to various factors, including valuation concerns or anticipated changes in the defense industry.

**4. Recent News & Significant Events**

*   **Mixed Sentiment:** The news headlines present a mixed picture.
    *   **Skepticism:** One article expresses skepticism about NOC as an S&P 500 stock.
    *   **Positive Analyst Action:** Goldman Sachs raised its price target, though maintaining a neutral rating.
    *   **Leadership Changes:** Former Northrop Grumman CEO joining another company suggests potential industry shifts.
    *   **Company Success:** Autonomous Docking Milestone.

**Impact:** The news suggests both potential challenges and positive developments for Northrop Grumman. The analyst price target increase is encouraging, but the skepticism highlighted in other articles warrants attention.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~2.05)
*   **Target Price (avg/high/low):** $623.28 / $769.00 / $524.00

**Analysis:**

*   **Positive Outlook:** The analyst consensus leans towards a "Buy" rating.
*   **Price Target Range:** There's a wide range in price targets, indicating differing opinions on the stock's potential. The current price is very close to the average target price, suggesting limited immediate upside according to the consensus.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출          |
|------------|-------|---------------|
| 2025-07-22 | 8.17  | 10.35 B$      |
| 2025-04-22 | 3.33  | 9.47 B$       |
| 2024-10-24 | 7.02  | 10.00 B$      |
| 2024-07-25 | 6.37  | 10.22 B$      |
| 2025-07-22 | 6.37  | 10.22 B$      |

**Analysis:**

*   **Mixed EPS:** EPS has been fluctuating, with a recent high in 2025-07-22.
*   **Stable Revenue:** Revenue has been relatively stable, generally around $10 billion per quarter.
*   **Growth Potential:** There's still growth potential because the last data is the same as another

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $10.35B   | 21.35%        |
| 2025-03-31 | $9.47B    | 16.69%        |
| 2024-12-31 | $10.69B   | 18.08%        |
| 2024-09-30 | $10.00B   | 21.07%        |
| 2024-06-30 | $10.22B   | 21.44%        |

Capital and Profitability:

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $15.47B   | 7.59%   |
| 2025-03-31 | $14.98B   | 3.21%   |
| 2024-12-31 | $15.29B   | 8.27%   |
| 2024-09-30 | $14.75B   | 6.96%   |
| 2024-06-30 | $14.30B   | 6.57%   |

**Analysis:**

*   **Strong Profitability:** Profit margins are consistently high, generally above 20%, indicating efficient operations.
*   **Growing Equity:** Equity has been steadily increasing, suggesting financial stability.
*   **Fluctuating ROE:** ROE has been fluctuating, but generally remains positive, indicating that the company is generating returns on its equity.

**7. Overall Summary**

*   **Underperformance vs. S&P 500:** Northrop Grumman has underperformed the S&P 500, both in terms of cumulative return and, in some periods, risk-adjusted performance (Alpha).
*   **Recent Positive Momentum:** The stock shows recent upward momentum, with the price above its moving averages.
*   **Overbought & Negative Long-Term Outlook:** The RSI indicates an overbought condition, and the expected return suggests potential long-term underperformance compared to the S&P 500.
*   **Mixed Signals:** Analyst opinions are generally positive, but recent news headlines present a mixed picture. The current price is close to the average analyst target.
*   **Solid Financials:** Northrop Grumman has strong profitability, growing equity, and generally positive ROE.

**Conclusion:**

Northrop Grumman presents a mixed investment picture. While the company exhibits solid financial performance and recent positive price momentum, its underperformance relative to the broader market and the negative long-term return projection are significant concerns. The overbought RSI suggests caution in the short term.

**Recommendation:**

Given the mixed signals, a **hold** or **neutral** rating might be appropriate. Investors should carefully weigh the company's strong financial position and recent positive momentum against its underperformance, overbought condition, and negative long-term outlook. Monitoring future earnings reports, industry developments, and analyst revisions is crucial. If you are a long-term investor, be wary of the negative expected return, even though the MRI suggests low risk.

